🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Castrate Resistance Prostate Cancer

Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan NCT06099093Phase 42 sites📍 Boston📍 Boston Brigham and Women's Hospital · Tests: 18F-DCFPyl Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177Lutetium-PSMA Radioligand Therapy: a Prospective Observational Study - KiRi-Trial NCT06720532n/a1 site📍 Munich Hannah Schaefer · Tests: characterization of renal function., Handgrip strength test, Questionaires Carboplatin or Olaparib for BRcA Deficient Prostate Cancer NCT04038502Phase 218 sites📍 West Los Angeles📍 Aurora📍 Washington D.C. VA Office of Research and Development · Tests: Carboplatin, Olaparib ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium NCT07414940Phase 1, Phase 21 site📍 London University College, London · Tests: Actinium (225Ac) rhPSMA-10.1 Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer NCT06738303Phase 21 site📍 Cleveland Case Comprehensive Cancer Center · Tests: Cabazitaxel and carboplatin, Lu-PSMA-617 TT-702 in Patients With Advanced Solid Tumours. NCT05272709Phase 1, Phase 23 sites📍 London📍 Manchester📍 Southampton Cancer Research UK · Tests: TT-702, Anti-PD-1 and PD-L1 agent Dapagliflozin Combined With Next-generation Hormonal Agent (NHA) Versus Single NHA in Participants With Metastatic Castrate-resistant Prostate Cancer NCT07310433Phase 22 sites📍 Shanghai📍 Shanghai Yung NA · Tests: Dapagliflozin (10mg Tab), standard medical care (ADT + NHA) Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer NCT05766371Phase 21 site📍 San Francisco University of California, San Francisco · Tests: Pembrolizumab, 177Lu-PSMA-617 Bipolar Androgen Therapy + Carboplatin in mCRPC NCT03522064Phase 21 site📍 Sydney St Vincent's Hospital, Sydney · Tests: Testosterone Enanthate 100 MG/ML Injectable Solution, Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplati… Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC NCT07090148Phase 11 site📍 Madison University of Wisconsin, Madison · Tests: pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) NCT04868604Phase 1, Phase 27 sites📍 Stanford📍 River Ridge📍 Grand Rapids Clarity Pharmaceuticals Ltd · Tests: 64Cu-SAR-bisPSMA, 67Cu-SAR-bisPSMA Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection NCT05413850Phase 1, Phase 221 sites📍 Miami📍 Miami📍 Atlanta Blue Earth Therapeutics Ltd · Tests: Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only) An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) NCT07206056Phase 1, Phase 235 sites📍 Denver📍 Jacksonville📍 Atlanta Novartis Pharmaceuticals · Tests: Tulmimetostat DL1 QD, Tulmimetostat DL2 QD, Tulmimetostat DL3 QD, Tulmimetostat Doses 1 or 2 QD, Tulmimetostat RP2D QD HER2 FPBMC in Patients With Metastatic Breast and Prostate Cancer (AM006) NCT07441889Phase 1, Phase 21 site📍 Charlottesville University of Virginia · Tests: HER2 FPBMC A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas NCT06999187Phase 110 sites📍 Denver📍 Orlando📍 Sarasota Dren Bio · Tests: DR-0202 Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer NCT05113537Phase 1, Phase 21 site📍 San Francisco Vadim S Koshkin · Tests: Abemaciclib, Lutetium Lu 177-PSMA-617 A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer NCT04729114Phase 125 sites📍 Tucson📍 Anaheim📍 Santa Rosa Astellas Pharma Global Development, Inc. · Tests: PRL-02 injection, prednisone, dexamethasone, enzalutamide Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T NCT06134232Phase 231 sites📍 Tuscon📍 Duarte📍 Fresno Dendreon · Tests: Sipuleucel-T Injection Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate Cancer NCT06702995Phase 1, Phase 22 sites📍 Jinan📍 Shanghai Evopoint Biosciences Inc. · Tests: XNW5004, enzalutamide Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body NCT06470243Phase 3174 sites📍 Fayetteville📍 Rogers📍 Springdale SWOG Cancer Research Network · Tests: Biospecimen Collection, Bone Scan, Cabazitaxel, Carboplatin, Chest Radiography A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma NCT03460977Phase 185 sites📍 Tucson📍 Tucson📍 Tucson Pfizer · Tests: Mevrometostat (PF-06821497), Enzalutamide, Itraconazole Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer NCT06800313Phase 1, Phase 218 sites📍 Colorado Springs📍 Denver📍 New Haven Janssen Research & Development, LLC · Tests: JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2, JNJ-101556143 Formulation 3 Trial of Acetylsalicylic Acid and Atorvastatin in Patients With Castrate-resistant Prostate Cancer NCT03819101Phase 330 sites📍 Olomouc📍 Villejuif📍 Besançon Gustave Roussy, Cancer Campus, Grand Paris · Tests: Acetylsalicylic acid, Atorvastatin Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer NCT07002320Phase 1, Phase 24 sites📍 Bellinzona📍 Belfast📍 Cambridge Institute of Cancer Research, United Kingdom · Tests: SX-682, Apalutamide Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) NCT06943495Phase 11 site📍 Québec Jean-Mathieu Beauregard · Tests: 177Lu-PSMA-617, 177Lu-PSMA-617 A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. NCT06629779Phase 3231 sites📍 Chandler📍 Gilbert📍 Glendale Pfizer · Tests: PF-06821497, Placebo, Enzalutamide Castrate Resistant Prostate Cancer Enhertu Therapy NCT06610825Phase 21 site📍 Washington D.C. Washington D.C. Veterans Affairs Medical Center · Tests: Enhertu Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors NCT07226713Phase 21 site📍 Milwaukee Medical College of Wisconsin · Tests: Pacritinib Clinical Outcomes of Use of Olaparib in Castration Resistant Prostate Cancer NCT06783127n/a2 sites📍 Naples📍 Trento Santa Chiara Hospital · Tests: Olaparib Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer NCT06927635Phase 21 site📍 Toronto University Health Network, Toronto · Tests: Stereotactic Body Radiation Therapy (SBRT), Systemic therapy
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy